Delving into the Latest Updates on Recombinant anti-human DR5 monoclonal antibody(Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

CTB-006

Target

DR5

Action

agonists

Mechanism

DR5 agonists(Tumor necrosis factor receptor superfamily member 10B agonists)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Beijing Cotimes Biotech Co., Ltd.

Active Organization

Beijing Cotimes Biotech Co., Ltd.

Lonn Ryonn PHARMA Ltd.

Inactive Organization

Sinotau Pharmaceutical Group

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：探索重组抗人DR5单克隆抗体注射液单药治疗晚期实体肿瘤的安全性与耐受性；次要目的：评估重组抗人DR5单克隆抗体注射液单药治疗晚期实体肿瘤的药代动力学特征；初步评估重组抗人DR5单克隆抗体注射液治疗晚期实体肿瘤的抗肿瘤活性；评估重组抗人DR5单克隆抗体注射液的免疫原性；

[Translation]

Primary purpose: To explore the safety and tolerability of recombinant anti-human DR5 monoclonal antibody injection as a monotherapy for advanced solid tumors; Secondary purpose: To evaluate the pharmacokinetic characteristics of recombinant anti-human DR5 monoclonal antibody injection as a monotherapy for advanced solid tumors; To preliminarily evaluate the antitumor activity of recombinant anti-human DR5 monoclonal antibody injection in the treatment of advanced solid tumors; To evaluate the immunogenicity of recombinant anti-human DR5 monoclonal antibody injection;

Start Date25 Jul 2018

Sponsor / Collaborator

Lonn Ryonn PHARMA Ltd.

[+1]

100 Clinical Results associated with Recombinant anti-human DR5 monoclonal antibody(Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi)

Login to view more data

100 Translational Medicine associated with Recombinant anti-human DR5 monoclonal antibody(Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi)

Login to view more data

100 Patents (Medical) associated with Recombinant anti-human DR5 monoclonal antibody(Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi)

Login to view more data

100 Deals associated with Recombinant anti-human DR5 monoclonal antibody(Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Beijing Cotimes Biotech Co., Ltd.	25 Jul 2018
Advanced Malignant Solid Neoplasm	Phase 1	China	Lonn Ryonn PHARMA Ltd.	25 Jul 2018
Solid tumor	Phase 1	China	Sinotau Pharmaceutical Group	25 Jul 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data